Resistant Catatonic Psychosis in an Adolescent With ASD/ADHD: Favorable Response to Lurasidone. A Clinical Case Report
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Revista de Psiquiatría Infanto-Juvenil
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
DOI:
https://doi.org/10.31766/revpsij.v42n4a5Keywords:
psychosis, ASD, ADHD, catatonia, lurasidoneAbstract
Introduction: Neurodevelopmental disorders such as autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) are conditions associated with the development of early-onset psychotic episodes. This comorbidity presents a challenge for child and adolescent psychiatry due to the potential interaction between these two disorders. Case description: This is a case report on a 14-year-old adolescent with ADHD and ASD who developed a first psychotic episode with catatonic symptoms following an increase in methylphenidate dosage. The condition was initially treatment-resistant, showing an insufficient response to aripiprazole, olanzapine, clonazepam and diazepam. Subsequently, the introduction of lurasidone led to a progressive clinical improvement and sustained stabilisation. Discussion/Conclusion: This case highlights the potential role of lurasidone as a therapeutic alternative in adolescents with ASD and psychosis presenting catatonic features refractory to standard treatments.
Downloads
References
De Anta Tejado L, Alonso Martína MV, Quintero J. Salud mental en la adolescencia (II). Psicosis y trastorno bipolar. Medicine (Madr). 2022;13(61): 3590-9. https://doi.org/10.1016/j.med.2022.08.002 DOI: https://doi.org/10.1016/j.med.2022.08.002
Crespo-Facorro B, Bernardo M, Argimon JM, Arrojo M, Bravo-Ortiz MF, Cabrera-Cifuentes A, et al. Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking. Rev Psiquiatr Salud Ment. 2017;10(1): 4-20. https://doi.org/10.1016/j.rpsm.2016.09.001 DOI: https://doi.org/10.1016/j.rpsm.2016.09.001
Remberk B, Szostakiewicz ?, Ka?wa A, Bogucka-Bonikowska A, Borowska A, Racicka E. What exactly is catatonia in children and adolescents. Psychiatr Pol. 2020;54(4): 759-75. https://doi.org/10.12740/PP/113013 DOI: https://doi.org/10.12740/PP/113013
Ungvari GS, Gerevich J, Takács R, Gazdag G. Schizophrenia with prominent catatonic features: A selective review. Schizophr Res. 2018;200: 77-84. https://doi.org/10.1016/j.schres.2017.08.008 DOI: https://doi.org/10.1016/j.schres.2017.08.008
Vaquerizo-Serrano J, Salazar De Pablo G, Singh J, Santosh P. Catatonia in autism spectrum disorders: A systematic review and meta-analysis. Eur Psychiatry. 2021;65(1): e4. https://doi.org/10.1192/j.eurpsy.2021.2259 DOI: https://doi.org/10.1192/j.eurpsy.2021.2259
Rogers JP, Oldham MA, Fricchione G, Northoff G, Ellen Wilson J, Mann SC, et al. Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2023;37(4): 327-69. https://doi.org/10.1177/02698811231158232
Rogers JP, Oldham MA, Fricchione G, Northoff G, Ellen Wilson J, Mann SC, Francis A, Wieck A, Elizabeth Wachtel L, Lewis G, Grover S, Hirjak D, Ahuja N, Zandi MS, Young AH, Fone K, Andrews S, Kessler D, Saifee T, Gee S, Baldwin DS, David AS. Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2023 Apr;37(4): 327-69. https://doi.org/10.1177/02698811231158232 DOI: https://doi.org/10.1177/02698811231158232
Samalin L, Garnier, Llorca P-M. Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag. 2011;7: 239. https://doi.org/10.2147/TCRM.S12701 DOI: https://doi.org/10.2147/TCRM.S12701
Bernardo M, Marsá MD, González-Pinto A, Carrasco MM, Sola VP, Sáiz PA, Vieta E, Torrens M, Arango C, Crespo-Facorro B. Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel. Neurol Ther. 2025 Feb;14(1): 85-98. https://doi.org/10.1007/s40120-024-00700-y DOI: https://doi.org/10.1007/s40120-024-00700-y
De Filippis S, Masi G, Serafini G, Vicari S, Vita A, Vitiello B. Dealing with Early-Onset Schizophrenia and the Role of Lurasidone: An Expert Opinion. Curr Neuropharmacol. 2025 Jul 15. https://doi.org/10.2174/011570159X385722250701114931 DOI: https://doi.org/10.2174/011570159X385722250701114931
Meza N, Franco JV, Sguassero Y, Núñez V, Escobar Liquitay CM, Rees R, Williams K, Rojas V, Rojas F, Pringsheim T, Madrid E. Atypical antipsychotics for autism spectrum disorder: a network meta-analysis. Cochrane Database Syst Rev. 2025 May 21;5(5): CD014965. https://doi.org/10.1002/14651858.CD014965.pub2 DOI: https://doi.org/10.1002/14651858.CD014965.pub2
© 2021 AEPNyA Todos los derechos reservados
